Showing 7751-7760 of 8879 results for "".
- Survey Highlights Increased Risk of Sunburn and Skin Cancer Among Outdoor Workershttps://practicaldermatology.com/news/survey-highlights-increased-risk-sunburn-and-skin-cancer-among-outdoor-workers/2463018/A recent survey conducted by the American Academy of Dermatology (AAD) highlighted the heightened risk of sunburn and skin cancer faced by outdoor workers in the United States. The survey, according to a press release, included responses from more than 1,000 U.S. adults and emphasized the
- Inside LEVEL UP: Lead Investigator Discusses Upadacitinib Studyhttps://practicaldermatology.com/news/inside-level-lead-investigator-discusses-upadacitinib-study/2463017/A recent study produced favorable topline results regarding the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an
- LEO Pharma Announces Topline Results of Phase 3 Trial in China for Plaque Psoriasis Treatment Enstilarhttps://practicaldermatology.com/news/leo-pharma-announces-topline-results-phase-3-trial-china-plaque-psoriasis-treatment-enstilar/2463007/LEO Pharma announced results from the Enstilar phase 3 trial in China in adult patients living with stable plaque psoriasis. The trial is a phase 3, randomised, investigator-blind, active controlled, parallel group, multicenter trial comparing the efficacy and safety of once daily Enstila
- Meta-Analysis: Avelumab Offers Hope for Advanced MCC Patientshttps://practicaldermatology.com/news/meta-analysis-avelumab-offers-hope-for-advanced-mcc-patients/2463006/A recent meta-analysis indicated that avelumab monotherapy and combination therapy shown improvement in overall response and survival rates in patients with advanced Merkel cell carcinomas (MCC). The study, published in Dermatologic Surgery, surveyed results from 48 studies invol
- Dermal Fillers Connected to Body Dysmorphia Disorder?https://practicaldermatology.com/news/dermal-fillers-connected-body-dysmorphia-disorder/2462981/A recent Forbes article suggests a potential connection between dermal fillers and body dysmorphic disorder (BDD), a condit
- Atopic Dermatitis Not Linked with Increased Risk for Venous Thromboembolismhttps://practicaldermatology.com/news/atopic-dermatitis-not-linked-increased-risk-venous-thromboembolism/2462969/A recent retrospective cohort study published in the latest issue of the Journal of the American Academy of Dermatology showed that venous thromboembolism (VTE) risk among patients with atopic dermatitis (AD) was lower than that of other immune-mediated inflammatory diseases (IMIDs).
- Acne Vulgaris Market Projected to Eclipse $10 Billion by 2034https://practicaldermatology.com/news/acne-vulgaris-market-projected-eclipse-10-billion-2034/2462961/The acne vulgaris market reached a value of US$ 7.0 Billion in 2023 and is anticipated to grow at a CAGR of 3.23% to more than $10 billion by 2034, according to a report by the IMARC Group. The rising popularity of light-based and laser therapies is partially responsible for this growth,
- Study: OTC Ointment Effective for Hydration and Wound Healing after Dermatologic Procedureshttps://practicaldermatology.com/news/otc-ointment-effective-hydration-wound-headling-dermatologic-procedures/2462940/Results from a two-study analysis in the Journal of Drugs in Dermatology suggested efficacy for an over-the-counter healing ointment (HO; Cetaphil Healing Ointment, Galderma Laboratories, LP, Dallas) in improving skin hydration and wound healing outcomes following dermatologic procedures
- Trifarotene Plus Skincare Effective Treatment for Acne-Induced Hyperpigmentationhttps://practicaldermatology.com/news/trifarotene-plus-skincare-effective-treatment-acne-induced-hyperpigmentation/2462920/Trifarotene combined with a skincare regimen was effective for the treatment of acne-induced hyperpigmentation (AIH) accompanying acne vulgaris (AV), according to results from a recent phase IV double-blind study. Researc
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t